Australia's largest stock trading and investment forum Australia's #1 stock forum

CDU

0.00%

23.5¢ cudeco limited

How can it survive?, page-4

First 4 Last

Share
Profile

Follow
ML173

9,583 Posts.

310

13/10/17

14:45

Post #: 27887757
Share

Originally posted by Bloomburger ↑

What i think is astonishing is how this company has survived for this long with only a few thousand tons being processed due to the difficulties with the Chinese processing plant.

This is their real current position and it seems Houdini would have trouble with this one.

So the next $20m of product has been sold to Mitsui. The $20m the company has said is going to Minsheng Bank as part of the loan arrangement scheme. $40m of debt to three lenders to be paid end October, end Dec and 10th Jan. 7 weeks to find $40m and no cash flow because all product (copper concentrates) going straight to Mitsui.

On top of all that the company has to pay a mining contractor and i guess 300+ personnel at the mine + fuel and other operating expenses.

So zero cash flow for the quater has already been paid and given the cash to Minsheng Bank.

Am I missing something here. How do you run a mining operation for 3 month with no cash? Who is going to lend a company with no history of cash flow and a mounting debt. There is not a hope in the world that the auditors can allow it even to relist let alone sign off, so unless something amazing happens it will stay in suspension.

The only real solution is that one of the Chinese privatise it or someone with mining experience makes a bid.
I suppose there is no real other possible ending to this saga.

I would be glad to have someone enlighten me with some other alternatives..

Expand

Why don’t you AMG guys do a mother of all mothers CR, and then launch the TO for CDU ?

CDU Price at posting: 37.0¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure